Abstract
OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have